{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T20:49:10Z","timestamp":1793566150987,"version":"4.5.0"},"reference-count":69,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Eisai UK","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2025,9,17]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>\n                    Lecanemab is an anti-amyloid monoclonal antibody, recently approved in the UK as a treatment for mild cognitive impairment (MCI) and mild dementia due to Alzheimer\u2019s disease (AD) in adults who are apolipoprotein E \u03b54 gene (\n                    <jats:italic>APOE4<\/jats:italic>\n                    ) heterozygotes or non-carriers.\n                  <\/jats:p>\n                  <jats:p>A group of UK neurologists, old age psychiatrists and geriatricians with expertise in AD convened to agree appropriate use recommendations for lecanemab in UK clinical practice. The primary focus of these recommendations is safety.<\/jats:p>\n                  <jats:p>\n                    Eligibility criteria for lecanemab in the UK include (a) a clinical diagnosis of MCI or mild dementia due to AD, (b) the presence of amyloid-\u03b2 pathology, confirmed using approved methods (ie, an amyloid positron emission tomography scan or cerebrospinal fluid assay) and (c)\n                    <jats:italic>APOE4<\/jats:italic>\n                    heterozygous or non-carrier status. Eligibility screening should be conducted in secondary care and those identified as being potentially eligible for lecanemab should be referred to a specialist centre for confirmation of the likely pathological diagnosis,\n                    <jats:italic>APOE4<\/jats:italic>\n                    counselling and testing and a multidisciplinary consensus decision regarding treatment eligibility. Lecanemab is administered as an intravenous infusion every 2 weeks, and those eligible for treatment should have brain magnetic resonance imaging (MRI) scans prior to the 1st, 5th, 7th and 14th infusions. Specific guidance is provided for safety monitoring and management of potential adverse reactions, including amyloid-related imaging abnormalities and infusion-related reactions.\n                  <\/jats:p>\n                  <jats:p>The introduction of lecanemab into UK clinical practice provides an important opportunity to improve services for all people living with dementia, not just those eligible for lecanemab treatment.<\/jats:p>","DOI":"10.1136\/jnnp-2025-336597","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T18:45:11Z","timestamp":1765651511000},"page":"372-384","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Lecanemab appropriate use recommendations for clinical practice in the UK"],"prefix":"10.1136","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6739-0803","authenticated-orcid":false,"given":"Catherine J","family":"Mummery","sequence":"first","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery, University College London, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4365-0428","authenticated-orcid":false,"given":"Jill","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Primary Care Specialist Dementia, Mental Health and Learning Disability, Surrey, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8886-1283","authenticated-orcid":false,"given":"Dan","family":"Blackburn","sequence":"additional","affiliation":[{"name":"Neuroscience, School of Medicine and Population Health, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0017-9595","authenticated-orcid":false,"given":"Elizabeth","family":"Coulthard","sequence":"additional","affiliation":[{"name":"Bristol Medical School, University of Bristol, Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8157-078X","authenticated-orcid":false,"given":"R Rhys","family":"Davies","sequence":"additional","affiliation":[{"name":"The Walton Centre NHS Foundation Trust, Liverpool, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Dorsey","sequence":"additional","affiliation":[{"name":"Imperial College London, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6660-657X","authenticated-orcid":false,"given":"Nick C","family":"Fox","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery and Queen Square Institute of Neurology, University College London, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0133-9842","authenticated-orcid":false,"given":"Akram A","family":"Hosseini","sequence":"additional","affiliation":[{"name":"Nottingham University Hospitals NHS Trust, Nottingham, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3690-2698","authenticated-orcid":false,"given":"Chineze","family":"Ivenso","sequence":"additional","affiliation":[{"name":"Aneurin Bevan University Health Board, Newport, Wales, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Jones","sequence":"additional","affiliation":[{"name":"Manchester Centre for Clinical Neurosciences, Salford Royal Hospital, Salford, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3721-0197","authenticated-orcid":false,"given":"Sean P","family":"Kennelly","sequence":"additional","affiliation":[{"name":"Department of Medical Gerontology, School of Medicine, Trinity College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5205-9712","authenticated-orcid":false,"given":"Christopher","family":"Kipps","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6758-0540","authenticated-orcid":false,"given":"Daniel","family":"Lashley","sequence":"additional","affiliation":[{"name":"University Hospitals Plymouth NHS Trust, Plymouth, Plymouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4316-2320","authenticated-orcid":false,"given":"Graham","family":"Mackay","sequence":"additional","affiliation":[{"name":"Aberdeen Royal Infirmary, Aberdeen, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4918-3647","authenticated-orcid":false,"given":"Rashi","family":"Negi","sequence":"additional","affiliation":[{"name":"Midlands Partnership NHS Foundation Trust, Lichfield, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9801-183X","authenticated-orcid":false,"given":"Ramin","family":"Nilforooshan","sequence":"additional","affiliation":[{"name":"Surrey and Borders Partnership NHS Foundation Trust, Surrey, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5738-6800","authenticated-orcid":false,"given":"Peter Anthony","family":"Passmore","sequence":"additional","affiliation":[{"name":"Queen\u2019s University Belfast, Belfast, Northern Ireland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4536-9018","authenticated-orcid":false,"given":"Richard","family":"Perry","sequence":"additional","affiliation":[{"name":"Imperial College London, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8238-4279","authenticated-orcid":false,"given":"Vanessa","family":"Raymont","sequence":"additional","affiliation":[{"name":"Oxford University, Oxford, Oxfordshire, UK"},{"name":"Oxford Health NHS Foundation Trust, Oxford, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7216-8679","authenticated-orcid":false,"given":"James Benedict","family":"Rowe","sequence":"additional","affiliation":[{"name":"Cambridge Centre for Frontotemporal Dementia, University of Cambridge, Cambridge, England, UK"},{"name":"Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9797-2188","authenticated-orcid":false,"given":"Tom C","family":"Russ","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland, UK"},{"name":"Neuroprogressive & Dementia Network, NHS Research Scotland, Dundee, Scotland, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7958-6558","authenticated-orcid":false,"given":"John-Paul","family":"Taylor","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9837-0645","authenticated-orcid":false,"given":"Alistair","family":"Burns","sequence":"additional","affiliation":[{"name":"Oxford Health NHS Foundation Trust, Oxford, England, UK"},{"name":"Manchester University, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"2026041508350832000_97.5.372.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30367-6"},{"key":"2026041508350832000_97.5.372.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01249-0)"},{"key":"2026041508350832000_97.5.372.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01484-7"},{"key":"2026041508350832000_97.5.372.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJ-Moa2212948"},{"key":"2026041508350832000_97.5.372.5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2100708"},{"key":"2026041508350832000_97.5.372.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"2026041508350832000_97.5.372.7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"2026041508350832000_97.5.372.8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/JAD-130029","article-title":"Specific uptake of an amyloid-\u03b2 protofibril-binding antibody-tracer in A\u03b2PP transgenic mouse brain","volume":"37","author":"Magnusson","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"2026041508350832000_97.5.372.9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3233\/JAD-140741","article-title":"The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice","volume":"43","author":"Tucker","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"2026041508350832000_97.5.372.10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21030952","article-title":"Protofibrils of Amyloid-\u03b2 are Important Targets of a Disease-Modifying Approach for Alzheimer\u2019s Disease","volume":"21","author":"Ono","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026041508350832000_97.5.372.11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126355","article-title":"Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer\u2019s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression","volume":"22","author":"Tolar","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026041508350832000_97.5.372.12","unstructured":"Eisai Ltd . Leqembi (lecanemab) summary of product characteristics. 2024. Available: https:\/\/www.medicines.org.uk\/emc\/product\/15908"},{"key":"2026041508350832000_97.5.372.13","unstructured":"National Institute for Health and Care Excellence . Final draft guidance finds benefits of 2 Alzheimer\u2019s treatments remain too small to justify the additional cost to the NHS. 2025. Available: https:\/\/www.nice.org.uk\/news\/articles\/the-benefits-of-alzheimers-treatments-donanemab-and-lecanemab-remain-too-small-to-justify-the-additional-costs-says-nice-in-final-draft-guidance [Accessed 20 Aug 2025]."},{"key":"2026041508350832000_97.5.372.14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"2026041508350832000_97.5.372.15","doi-asserted-by":"crossref","unstructured":"van Dyck CH , Sperling RA , Dhadda S , et al . Is there Evidence for a Continued Benefit for Long\u2010Term Lecanemab Treatment? A Benefit\/Risk Update from Long\u2010Term Efficacy, Safety and Biomarker Data. Alzheimers Dement 2024;20. doi:10.1002\/alz.092094","DOI":"10.1002\/alz.092094"},{"key":"2026041508350832000_97.5.372.16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trci.2016.01.001","article-title":"Design of a Bayesian adaptive phase 2 proof\u2010of\u2010concept trial for BAN2401, a putative disease\u2010modifying monoclonal antibody for the treatment of Alzheimer\u2019s disease","volume":"2","author":"Satlin","year":"2016","journal-title":"Alzheimers Dement (N Y)"},{"key":"2026041508350832000_97.5.372.17","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"2026041508350832000_97.5.372.18","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12748"},{"key":"2026041508350832000_97.5.372.19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1192\/bjp.2023.166","article-title":"Estimating demand for potential disease-modifying therapies for Alzheimer\u2019s disease in the UK","volume":"224","author":"Laurell","year":"2024","journal-title":"Br J Psychiatry"},{"key":"2026041508350832000_97.5.372.20","unstructured":"US Food and Drug Administration . (Lecanemab-irmb) prescribing information. 2023. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761269s000lbl.pdf"},{"key":"2026041508350832000_97.5.372.21","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: Appropriate Use Recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"2026041508350832000_97.5.372.22","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1212\/WNL.0000000000207757","article-title":"Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology","volume":"101","author":"Ramanan","year":"2023","journal-title":"Neurology (ECronicon)"},{"key":"2026041508350832000_97.5.372.23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40263-024-01097-w","article-title":"A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer\u2019s Disease","volume":"38","author":"Rosenbloom","year":"2024","journal-title":"CNS Drugs"},{"key":"2026041508350832000_97.5.372.24","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100094","article-title":"Lecanemab for early Alzheimer\u2019s disease: Appropriate use recommendations from the French federation of memory clinics","volume":"12","author":"Villain","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"2026041508350832000_97.5.372.25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.12779\/dnd.2024.23.4.165","article-title":"Lecanemab: Appropriate Use Recommendations by Korean Dementia Association","volume":"23","author":"Park","year":"2024","journal-title":"Dement Neurocogn Disord"},{"key":"2026041508350832000_97.5.372.26","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1474-4422(23)00274-0","article-title":"Preparing for disease-modifying therapies in Alzheimer\u2019s disease","volume":"22","author":"Belder","year":"2023","journal-title":"Lancet Neurol"},{"key":"2026041508350832000_97.5.372.27","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-333468"},{"key":"2026041508350832000_97.5.372.28","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41582-024-01022-1","article-title":"Preparing for disease-modifying dementia therapies in the UK","volume":"20","author":"Cooper","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"2026041508350832000_97.5.372.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53221.x"},{"key":"2026041508350832000_97.5.372.30","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1610"},{"key":"2026041508350832000_97.5.372.31","doi-asserted-by":"publisher","DOI":"10.1159\/000351671"},{"key":"2026041508350832000_97.5.372.32","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.121.319949"},{"key":"2026041508350832000_97.5.372.33","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A7586"},{"key":"2026041508350832000_97.5.372.34","doi-asserted-by":"crossref","DOI":"10.1002\/trc2.12117","article-title":"APOE \u03b54\/\u03b54 homozygotes with early Alzheimer\u2019s disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline","volume":"6","author":"Abushakra","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"key":"2026041508350832000_97.5.372.35","doi-asserted-by":"publisher","DOI":"10.1017\/s104161021700268x"},{"key":"2026041508350832000_97.5.372.36","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.jamda.2022.03.018","article-title":"Conversion Between the Mini-Mental State Examination and the Montreal Cognitive Assessment for Patients With Different Forms of Dementia","volume":"23","author":"Roheger","year":"2022","journal-title":"J Am Med Dir Assoc"},{"key":"2026041508350832000_97.5.372.37","doi-asserted-by":"publisher","DOI":"10.1111\/JGS.18124"},{"key":"2026041508350832000_97.5.372.38","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"2026041508350832000_97.5.372.39","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2030","article-title":"Self administered cognitive screening test (TYM) for detection of Alzheimer\u2019s disease: cross sectional study","volume":"338","author":"Brown","year":"2009","journal-title":"BMJ"},{"key":"2026041508350832000_97.5.372.40","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics9030116","article-title":"Test Your Memory (TYM) and Test Your Memory for Mild Cognitive Impairment (TYM-MCI): A Review and Update Including Results of Using the TYM Test in a General Neurology Clinic and Using a Telephone Version of the TYM Test","volume":"9","author":"Brown","year":"2019","journal-title":"Diagnostics (Basel)"},{"key":"2026041508350832000_97.5.372.41","doi-asserted-by":"publisher","DOI":"10.1017\/S003329170002691X"},{"key":"2026041508350832000_97.5.372.42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1992.tb01796.x"},{"key":"2026041508350832000_97.5.372.43","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afw039"},{"key":"2026041508350832000_97.5.372.44","unstructured":"NHS England . Identifying frailty. 2024. Available: https:\/\/www.england.nhs.uk\/ourwork\/clinical-policy\/older-people\/frailty\/frailty-risk-identification\/ [Accessed 13 May 2024]."},{"key":"2026041508350832000_97.5.372.45","unstructured":"National institute for health and care excellence . Clinical knowledge summary (CKS): Dementia. 2024. Available: https:\/\/cks.nice.org.uk\/topics\/dementia\/ [Accessed 18 Apr 2024]."},{"key":"2026041508350832000_97.5.372.46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260506","article-title":"Key components of post-diagnostic support for people with dementia and their carers: A qualitative study","volume":"16","author":"Bamford","year":"2021","journal-title":"PLoS One"},{"key":"2026041508350832000_97.5.372.47","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1108\/HE-08-2017-0042","article-title":"Post-diagnostic support for dementia: What can be learned from service providers\u2019 experiences, model variation and information recording","volume":"118","author":"Levin","year":"2018","journal-title":"Health Educ"},{"key":"2026041508350832000_97.5.372.48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol"},{"key":"2026041508350832000_97.5.372.49","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0228-7"},{"key":"2026041508350832000_97.5.372.50","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2802"},{"key":"2026041508350832000_97.5.372.51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13195-020-00740-0","article-title":"The association of APOE \u03b54 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study","volume":"13","author":"Gharbi-Meliani","year":"2021","journal-title":"Alz Res Therapy"},{"key":"2026041508350832000_97.5.372.52","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.117"},{"key":"2026041508350832000_97.5.372.53","doi-asserted-by":"crossref","first-page":"211","DOI":"10.14283\/jpad.2022.21","article-title":"Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer\u2019s Disease Treated with Anti-Amyloid Beta Therapy","volume":"9","author":"Barakos","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"2026041508350832000_97.5.372.54","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","article-title":"Amyloid-Related Imaging Abnormalities and \u03b2-Amyloid\u2013Targeting Antibodies","volume":"79","author":"Filippi","year":"2022","journal-title":"JAMA Neurol"},{"key":"2026041508350832000_97.5.372.55","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad188"},{"key":"2026041508350832000_97.5.372.56","doi-asserted-by":"crossref","unstructured":"Janson CG . AD and CAA: Independent risk factors for dementia. Sci Transl Med 2015;7. doi:10.1126\/scitranslmed.aad9005","DOI":"10.1126\/scitranslmed.aad9005"},{"key":"2026041508350832000_97.5.372.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2351"},{"key":"2026041508350832000_97.5.372.58","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A3500"},{"key":"2026041508350832000_97.5.372.59","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70015-7"},{"key":"2026041508350832000_97.5.372.60","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol"},{"key":"2026041508350832000_97.5.372.61","article-title":"Symptomatic amyloid-related imaging abnormalities in an APOE \u03b54\/\u03b54 patient treated with aducanumab","volume":"12","author":"VandeVrede","year":"2020","journal-title":"Alzheimers Dement (Amst)"},{"key":"2026041508350832000_97.5.372.62","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jamaneurol.2020.1782","article-title":"Association Between Immunosuppressive Treatment and Outcomes of Cerebral Amyloid Angiopathy-Related Inflammation","volume":"77","author":"Regenhardt","year":"2020","journal-title":"JAMA Neurol"},{"key":"2026041508350832000_97.5.372.63","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2015.14","article-title":"Clinical development methodology for infusion-related reactions with monoclonal antibodies","volume":"4","author":"Doessegger","year":"2015","journal-title":"Clin Transl Immunology"},{"key":"2026041508350832000_97.5.372.64","unstructured":"US Food and Drug Administration . Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials 2007. 2007. Available: https:\/\/www.fda.gov\/media\/73679\/download [Accessed 29 May 2025]."},{"key":"2026041508350832000_97.5.372.65","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.14283\/jpad.2024.159","article-title":"Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center","volume":"11","author":"Shields","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"2026041508350832000_97.5.372.66","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40120-025-00756-4","article-title":"Characterizing the Journey of Early Alzheimer\u2019s Disease in Patients Initiating Lecanemab Treatment in the United States: A Real-World Evidence Study","volume":"14","author":"Sabbagh","year":"2025","journal-title":"Neurol Ther"},{"key":"2026041508350832000_97.5.372.67","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-025-01763-1","article-title":"Lecanemab in clinical practice: real-world outcomes in early Alzheimer\u2019s disease","volume":"17","author":"Bregman","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"2026041508350832000_97.5.372.68","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","article-title":"Lecanemab Treatment in a Specialty Memory Clinic","volume":"82","author":"Paczynski","year":"2025","journal-title":"JAMA Neurol"},{"key":"2026041508350832000_97.5.372.69","unstructured":"Eisai . LEQEMBI\u00ae\u201d (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer\u2019s Disease Approved in the United Kingdom; press release.. 2025. Available: https:\/\/www.eisai.com\/news\/2025\/news202579.html [Accessed 1 December 2025]."}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2025-336597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:36:01Z","timestamp":1776267361000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2025-336597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":69,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,4,15]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/jnnp-2025-336597"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2025-336597","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]}}}